Dr Tilmann Buerckstuemmer

Tilmann is a biochemist by training. After a PhD at the Robert-Koch-Institute in Berlin and a postdoctoral stay with Giulio Superti-Furga, he joined Haplogen as Principal Scientist and, later, Head of Research. With the advent of CRISPR, Tilmann focused his team on CRISPR gene editing and quickly produced the largest collection of isogenic human knockout cell lines available to date. This became the basis for the commercial success of Haplogen Genomics and its acquisition by Horizon Discovery. At Horizon, Tilmann served as R&D Director and Head of Innovation with global oversight of all R&D projects. In early 2018, Tilmann decided to found Aelian Biotechnology, where he currently serves as CSO, together with partners. He is passionate about science and enjoys working with multi-disciplinary and multi-national teams.